Urology Group | Strategic Alliance Partners

“The way to move the organization forward is to listen to learn, not to win,” says J. Stuart Wolf, Jr., MD, FACS.

“I cannot overstate the impact of this device on my management of kidney stone patients," says J. Stuart Wolf, Jr., MD, FACS.

"Continuing certification is not merely a bureaucratic process; it is a commitment to staying abreast of advancements in urology and maintaining competencies," writes J. Stuart Wolf Jr, MD, FACS.

“Gone are the days when scalpel was king or queen in this space. The armamentarium of medications and systemic treatments, combination treatments has exploded, and our understanding of the biology of disease is expanding,” says Harras B. Zaid, MD.

“I think we should all be pretty selective in whom we're operating on in the metastasectomy setting,” says Harras B. Zaid, MD.

"Again, operating has more and more taken a backseat as the armamentarium of systemic medications, especially checkpoint inhibitors [and] combination treatments, has exploded," says Harras B. Zaid, MD.

“There has been a stage migration in part related to the availability of cross-sectional imaging, but there's still a proportion of patients who present with locally advanced disease,” says Harras B. Zaid, MD.

"One of the biggest surprises was just how ubiquitous prescribing narcotics in all phases were, from intraoperatively to the PACU to postoperatively," says Aaron A. Laviana, MD, MBA.